Thermo Fisher Scientific(US:TMO) 仪器信息网·2025-06-04 09:01Core Viewpoint - Thermo Fisher Scientific launched two innovative mass spectrometers, Orbitrap Astral Zoom and Orbitrap Excedion Pro, at ASMS 2025, aimed at advancing research in complex biological processes and major diseases such as Alzheimer's and cancer, thereby enhancing precision medicine and biopharmaceutical development [1][2]. Group 1: Orbitrap Astral Zoom Highlights - The Orbitrap Astral Zoom features a 35% increase in scanning speed, facilitating rapid data collection [4]. - It offers a 40% improvement in throughput, supporting large-scale sample screening [4]. - The system enhances multi-detection capabilities by 50%, enabling multidimensional analysis in a single experiment [4]. - Applications include deep proteomics analysis and trace biomarker discovery [4]. Group 2: Orbitrap Excedion Pro Highlights - The Orbitrap Excedion Pro integrates next-generation Orbitrap technology with complementary fragmentation techniques, providing breakthrough solutions for analyzing complex biomolecules [7]. - It accelerates biopharmaceutical development by enabling in-depth analysis of monoclonal antibodies and other biological therapeutics [7]. - Enhanced sensitivity, dynamic range, and reliability allow for simultaneous high-quality data on proteins and post-translational modifications [9]. - The system supports research in cardiovascular diseases, neuroscience, and oncology [7]. Group 3: Overall Impact and Ecosystem - Both instruments strengthen Thermo Fisher's "end-to-end" research ecosystem, which includes reagents, imaging systems, and advanced mass spectrometry workflows [7]. - They provide robust support for proteomics, biopharmaceutical characterization, and translational medicine, focusing on disease mechanism research and target validation [7].